Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Fundamental, Research

Implications of the Medicare Price Negotiations Announcement for BMY and JNJ

Sel Hardy, VP of Equity Research

05 September 2023

Summary

The Centers for Medicare & Medicaid Services (CMS) released a list of 10 top-selling prescription drugs to be negotiated with Medicare. The market reaction has been limited as the list was expected. Companies' revenue risk is manageable as the drugs selected are no longer a large portion of their portfolios. Some drugs will lose their exclusivity around or after 2026, when the negotiated prices go into effect. Bristol Myers Squibb and Johnson & Johnson are at highest risk of revenue loss by 2026.

Want to learn more? Download the Report.

Solutions

Fundamental Equity Research

Gain a comprehensive view of global themes, industries, and companies.

Related Insights

FDA Action on Aspartame Unlikely

FDA Action on Aspartame Unlikely

Recent reports that the World Health Organization (WHO) will reclassify aspartame...

Johnson & Johnson (JNJ): Texas Two-Step Takes a Spill

Johnson & Johnson (JNJ): Texas Two-Step Takes a Spill

Johnson & Johnson (JNJ: Talc Bankruptcy Opinion and Implications

May 2023 PDUFA Calendar

May 2023 PDUFA Calendar

Delays in approvals due to disrupted work schedules at FDA because of the coronavirus...